InVitria launches Zap-SR as substitute to address bovine serum shortage

InVitria launches Zap-SR as substitute to address bovine serum shortage

FORT COLLINS - InVitria announced the commercial launch of its Zap-SR (Serum Reducer), a product for cell culture customers who currently use fetal bovine serum and are concerned about... Read More

By: InnovatioNews Wednesday November 26, 2014 0 comments Tags: cell culture, Dr. Randall Alfano, Fort Collins, InVitria, Scott Deeter, Zap--SR

Ventria Bioscience acquires Meristem Therapeutics' Recombinant Lactoferrin IP

Ventria Bioscience acquires Meristem Therapeutics' Recombinant Lactoferrin IP

FORT COLLINS - Ventria Bioscience will wholly acquire portions of the intellectual property portfolio relating to Recombinant Lactoferrin developed by the French biotech company Meristem... Read More

By: Steve Tuesday December 4, 2012 0 comments Tags: ExpressTec, Fort Collins, Scott Deeter, VEN100, Ventria Bioscience

Ventria Bioscience: Study shows Optiferrin is comparable to human transferrin

Ventria Bioscience: Study shows Optiferrin is comparable to human transferrin

FORT COLLINS - Ventria Bioscience announced that its Optiferrin product has been shown to be biochemically and structurally similar to human transferrin molecules derived from human serum or a... Read More

By: Steve Tuesday October 9, 2012 0 comments Tags: Express Tec, Fort Collins, InVitria, Optiferrin, Scott Deeter, transferrin, Ventria Bioscience

Ventria Bioscience and UC-Denver awarded grant to study acetaminophen overdose-induced liver failure

Ventria Bioscience and UC-Denver awarded grant to study acetaminophen overdose-induced liver failure

FORT COLLINS - Ventria Bioscience has received notification of approximately $200,000 in funding for a research proposal to study treatment of acetaminophen overdose-induced liver failure,... Read More

By: Steve Tuesday September 4, 2012 0 comments Tags: Cynthia Ju, Scott Deeter, Ventria Bioscience

InVitria receives $1.5 million grant for cell-based vaccines

FORT COLLINS - InVitria, a division of Ventria Bioscience, announced it will receive $1.5 million over two years to develop a novel, animal-free, defined cell culture media for the commercial... Read More

By: Jay Jacoby Wednesday May 30, 2012 0 comments Tags: cell-based vaccines, InVitria, Scott Deeter, Ventria Bioscience